Effects of a Novel COL4A3 Homozygous/Heterozygous Splicing Mutation on the Mild Phenotype in a Family With Autosomal Recessive Alport Syndrome and a Literature Review
Molecular Genetics & Genomic Medicine · 2025
DOI: 10.1002/mgg3.70053 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Genetics & Genomic Medicine, 2025. Verfasst von Dan Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Affiliated Hospital of Guizhou Medical University, Guizhou Provincial Children's Medical Center, Guiyang, Guizhou, Chin…. Hauptthemen laut MEDLINE: Collagen Type IV, Nephritis, Hereditary, Autoantigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Fund project of Guizhou Provincial Health Commission in 2024, Guizhou Province Overseas Returned Talents Innovation and Entrepreneurship Merit-based Support Project.
Abstract (Originalsprache)
Background
Alport syndrome involves chronic progressive kidney failure and extrarenal organ damage caused by COL4A3 , COL4A4 , and COL4A5 mutations.
Methods
We initially discerned a COL4A3 splicing mutation via next‐generation sequencing. Next, we used bioinformatics, renal biopsy pathology, and an in vitro minigene experiment. Complementary analysis of clinical data was carried out, and we explored the expression and function of the variants to verify their pathogenicity.
Results
A splicing mutation (c.687 + 1G > T) in COL4A3 was found in a Chinese family. Bioinformatics analysis revealed its impact on splicing, causing a translational frameshift, which was confirmed by an in vitro minigene assay. The proband's glomerular basement membrane displayed reduced type IV collagen α3, α4, and α5 chains, with some absent, suggesting disruption of collagen IV trimers in the glomerular basement membrane, potentially damaging the glomerular filtration barrier.
Conclusion
We present a novel finding of a previously unreported c.687 + 1G > T mutation in COL4A3 that disrupts transcription and translation, impairing α3α4α5 (IV) chain formation, altering the integrity of the glomerular basement membrane, causing hereditary Alport syndrome. This discovery enriches the genetic map of Alport syndrome, aiding in clinical genetic guidance, and enhancing the efficacy of prenatal testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The Affiliated Hospital of Guizhou Medical University, Guizhou Provincial Children's Medical Center, Guiyang, Guizhou, China.
- Department of Pathology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
ORCID-Profile: Dan Chen
Förderung
- Science and Technology Fund project of Guizhou Provincial Health Commission in 2024
- Guizhou Province Overseas Returned Talents Innovation and Entrepreneurship Merit-based Support Project
Zitieren
APA
Chen, D., Zhang, L., Rao, J., Zhou, Y., Dai, L., Huang, S., Yang, C., Bian, Q., Zhang, T., & Yang, X. (2025). Effects of a Novel COL4A3 Homozygous/Heterozygous Splicing Mutation on the Mild Phenotype in a Family With Autosomal Recessive Alport Syndrome and a Literature Review. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70053
Vancouver
Chen D, Zhang L, Rao J, Zhou Y, Dai L, Huang S, et al. Effects of a Novel COL4A3 Homozygous/Heterozygous Splicing Mutation on the Mild Phenotype in a Family With Autosomal Recessive Alport Syndrome and a Literature Review. Molecular Genetics & Genomic Medicine. 2025. doi:10.1002/mgg3.70053
BibTeX
@article{Chen2025,
author = {Chen, Dan and Zhang, Li and Rao, Jing and Zhou, Yan and Dai, Lujun and Huang, Songsong and Yang, Chunxia and Bian, Qiuhan and Zhang, Tao and Yang, Xiaoyan},
title = {Effects of a Novel COL4A3 Homozygous/Heterozygous Splicing Mutation on the Mild Phenotype in a Family With Autosomal Recessive Alport Syndrome and a Literature Review},
journal = {Molecular Genetics & Genomic Medicine},
year = {2025},
doi = {10.1002/mgg3.70053}
}
EUVIMED